143 related articles for article (PubMed ID: 37478162)
1. Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects.
Landa I; Thornton CEM; Xu B; Haase J; Krishnamoorthy GP; Hao J; Knauf JA; Herbert ZT; Martínez P; Blasco MA; Ghossein R; Fagin JA
Mol Cancer Res; 2023 Nov; 21(11):1163-1175. PubMed ID: 37478162
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reactivation induces progression of mouse Braf
Landa I; Thornton CE; Xu B; Haase J; Krishnamoorthy GP; Hao J; Knauf JA; Herbert ZT; Blasco MA; Ghossein R; Fagin JA
bioRxiv; 2023 Jan; ():. PubMed ID: 36747657
[TBL] [Abstract][Full Text] [Related]
3. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):515-525. PubMed ID: 32981294
[TBL] [Abstract][Full Text] [Related]
5. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
6. InTERTwined: how
Landa I
Curr Opin Endocr Metab Res; 2023 Jun; 30():. PubMed ID: 37576936
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
9. HIF-1α-Mediated Telomerase Reverse Transcriptase Activation Inducing Autophagy Through Mammalian Target of Rapamycin Promotes Papillary Thyroid Carcinoma Progression During Hypoxia Stress.
Song H; Chen X; Jiao Q; Qiu Z; Shen C; Zhang G; Sun Z; Zhang H; Luo QY
Thyroid; 2021 Feb; 31(2):233-246. PubMed ID: 32772829
[No Abstract] [Full Text] [Related]
10. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
12. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
13. Telomerase and Telomeres Biology in Thyroid Cancer.
Donati B; Ciarrocchi A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200515
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
17. Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules.
Giorgenon TMV; Carrijo FT; Arruda MA; Cerqueira TLO; Barreto HR; Cabral JB; Silva TMD; Magalhães PKR; Maciel LMZ; Ramos HE
Arch Endocrinol Metab; 2019; 63(2):107-112. PubMed ID: 30916166
[TBL] [Abstract][Full Text] [Related]
18. Multiple ETS Factors Participate in the Transcriptional Control of
Thornton CEM; Hao J; Tamarapu PP; Landa I
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053525
[TBL] [Abstract][Full Text] [Related]
19. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
Chen B; Shi Y; Xu Y; Zhang J
Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
